|
PRODUCT TYPE:- PREVASTATIN
|
|
BRAND NAME |
STRENGTH |
PACKING |
PRICE |
|
PRAVASTATIN : It is a competitive inhibitor of 3-hydroxy-3-methylgulatryl-coenzyme A (HMG-COA) reductase the enzyme catalysing the early rate limiting step in cholesterol biosynthesis it affects medoest reductions in intracellular pools of choles terol which result is an increased number of LDL receptors on cell surface inhanceed receptor-mediated catabolism and clearance of circulating low density lipoprotein cholesterol (LDL-C) It also om hibits LDL-C production by inhibiting hepatic synthesis of very low density lipoprotein (VLDL-C)the LDL-C precursor. These effects result in a reduction of toal cholesterol (Total-C) LDL-C VLDL-C apolipoprotein B and triglyceried whilst increasing high density liportein chloesterol (HDL-C_ and apoliprotein A.
Indications: Atheropsclerrosis related clinical events as a funtion of cholesterol level the presence or absence of coronary heart diease, and other risk factors. Hyperlipidemia. Treatment of patients with primary dysbetaliporproteinemia (Fredrickson Type III)
Dosage: Initial dose: 10 to 20mg or 40mg once daily at bedtime
Renal/Heptic function impairment : A starting dose of 10mg/day at bedtime is recommended
Side effect: Rash myalgia headache non-cardiac chest pain rarely nausea/vomiting diarrhea and fatigue may occur
Contra Indications: Hypersensitivity acute liver disease or unexplained presistent elevation in liver functions tests.
Special Precautions Perform liver function test before initiating therapy and at 12 weeks therafter Monitor patients with renal impairment may elevate creatine phosphokinase and transminase levels Pregnancy Breast feeding
Drug Interactions : Bile acid squestrants (BAS).